|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma.
|
12579211 |
2002 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, the present study aimed to elucidate the relationship between NPM and Her-2 in gastric cancer cell lines and clinical samples, and further investigated their role in the resistance of gastric cancer to oxaliplatin.
|
28454407 |
2017 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
|
21505336 |
2011 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier.
|
21058730 |
2010 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data suggest that immuno-liposome mediated delivery of drugs is a promising new therapeutic option for patients with advanced gastric cancer that overexpress Her2/neu.
|
21109923 |
2011 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2 detection in mixed gastric carcinoma displays high heterogeneity.
|
25914479 |
2015 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, the clinical significance of multi-targeting tyrosine kinase inhibitors (TKIs) in HER2-positive gastric cancer remains unclear.
|
31704817 |
2019 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
c-erbB-2 oncogene has been reported to be frequently amplified in differentiated, tubular type of gastric cancer.
|
2575609 |
1989 |
|
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Although the prevalence of Her-2/neu over-expression in gastric cancer has been reported across the world, it is still unknown from South Asia.
|
29806596 |
2018 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Gastric cancer (GC) has also been slow to benefit from biomarker discovery and development and the successful utilisation of targeted therapies, with the exception of trastuzumab in HER2 positive cancers.
|
30597479 |
2019 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The anti-ErbB2 antibody trastuzumab has currently been approved for ErbB2-positive gastric cancer.
|
24668364 |
2014 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Intratumoral heterogeneity of HER2 expression in the metastatic foci of HER2-positive advanced gastric cancer remains unclear.
|
25828363 |
2015 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Consensus guidelines have standardized the testing of HER2 status in gastric cancer.
|
23021388 |
2013 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Patients with chemotherapy-naive HER2-positive advanced gastric cancer were eligible.
|
26857702 |
2016 |
|
Stomach Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Focal HER2 gene amplification was more common in GCs with no (0 and 1+) or low (2+) HER2 expression.
|
22437741 |
2012 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Correlations between the expression levels of miR-21, PTEN, and p-AKT were analyzed by real-time PCR and Western blot test in HER2-positive GC cell lines.
|
24154840 |
2014 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Clinical significance of intratumoral HER2 heterogeneity in gastric cancer.
|
23146959 |
2013 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Forty-two HER2-positive GC samples from patients treated with trastuzumab-based first-line chemotherapy were selected.DNA samples were sequenced.
|
29700210 |
2018 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The HER2 protein, encoded by the ERBB2 gene, is a molecular target for the treatment of breast and gastric cancer by monoclonal antibodies or tyrosine kinase inhibitors.
|
22899293 |
2012 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2-ECD (human epidermal growth factor receptor 2 - extracellular domain) is a prominent therapeutic target validated for treating HER2-positive breast and gastric cancer, but HER2-specific therapeutic options for treating advanced gastric cancer remain limited.
|
30365359 |
2019 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Human epidermal growth factor receptor 2 status in gastric carcinoma is comparable to previous studies with good concordance between IHC and SISH; all IHC 2+ and unusual patterns should be assessed with ISH studies; heterogeneity of tumour HER2 overexpression/amplification is common with possible implications for HER2 testing; and HER2 overexpression appears sufficiently specific to be considered a potential diagnostic biomarker of dysplasia.
|
22092394 |
2011 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Few studies focus on the feasibility of trastuzumab as maintenance or palliative therapy for patients with HER2-positive advanced GC.
|
30275713 |
2018 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Based on Hoffmann's criteria in gastric cancer, three models (PDGAX001, PDGAX003 and PDGAX005) were defined as HER-2 positive with fluorescence in situ hybridization (FISH) amplification or immunohistochemistry (IHC) 2+/ 3+, while two models (PDGAX002, PDGAX004) were defined as HER-2 negative.
|
25749810 |
2015 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study aimed to explore the molecular segmentation of several known therapeutics targets, human epidermal growth factor receptor 2 (HER2), MET and fibroblast growth factor receptor 2 (FGFR2), within GC using clinically approved or investigational kits and scoring criteria.
|
24518603 |
2014 |
|
Stomach Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In a subpopulation study, although HER-2 positivity emerged as a favorable prognostic factor for stage III-IV gastric cancer on univariate analysis, it failed to be an independent prognostic factor after multivariate adjustment.
|
22143936 |
2011 |